Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04250922Phase 2Active Not Recruiting

LAM561 With RT and TMZ for Adults With Glioblastoma

Role: collaborator

NCT03009799Phase 2Withdrawn

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)

Role: collaborator

NCT01299545Terminated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Role: collaborator

All 3 trials loaded